טוען...
Monitoring therapeutic monoclonal antibodies in brain tumor
Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target ti...
שמור ב:
| הוצא לאור ב: | MAbs |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622724/ https://ncbi.nlm.nih.gov/pubmed/25484065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.34405 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|